Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Shorter disease duration is important for tocilizumab to achieve Boolean remission.

Kawasaki Y, Hashimoto T, Okano T, Sakai Y, Yamane T, Shiozawa K, Shiozawa S, Hashiramoto A.

Mod Rheumatol. 2013 Nov;23(6):1192-7. doi: 10.1007/s10165-012-0822-7.

PMID:
23380997
2.

The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab.

Hirabayashi Y, Ishii T; Michinoku Tocilizumab Study Group..

Clin Rheumatol. 2013 Jan;32(1):123-7. doi: 10.1007/s10067-012-2103-4.

3.

Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab.

Hoshi D, Nakajima A, Shidara K, Seto Y, Tanaka E, Taniguchi A, Momohara S, Yamanaka H.

Mod Rheumatol. 2013 Nov;23(6):1205-10. doi: 10.1007/s10165-012-0825-4.

PMID:
23456321
4.

Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice.

Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, Yabe Y, Kato T, Terabe K, Fukaya N, Tsuchiya H, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Ishiguro N.

Mod Rheumatol. 2012 Jun;22(3):370-5. doi: 10.1007/s10165-011-0528-2.

PMID:
21931942
5.

Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.

Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Asai S, Hirabara S, Asai N, Hirano Y, Hayashi M, Miyake H, Kojima M, Ishiguro N.

Rheumatology (Oxford). 2015 Jan;54(1):113-20. doi: 10.1093/rheumatology/keu302.

6.

Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.

Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, Troum O, Aassi M, Bernasconi C, Dougados M.

Ann Rheum Dis. 2015 Jan;74(1):35-43. doi: 10.1136/annrheumdis-2014-205752.

7.

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria.

Iking-Konert C, Aringer M, Wollenhaupt J, Mosch T, Tuerk S, Feist E, Burmester GR.

Ann Rheum Dis. 2011 Nov;70(11):1986-90. doi: 10.1136/ard.2011.152678.

8.

[Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].

Avdeeva AS, Aleksandrova EN, Novikov AA, Cherkasova MV, Panasyuk EY, Nasonov EL.

Ter Arkh. 2013;85(5):24-9. Russian.

PMID:
23819335
11.

Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.

Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Ueki Y, Migita K, Mizokami A, Origuchi T, Aoyagi K, Eguchi K.

Mod Rheumatol. 2011 Aug;21(4):365-9. doi: 10.1007/s10165-010-0402-7.

PMID:
21229375
12.

Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.

Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.

Mod Rheumatol. 2013 Jul;23(4):782-7. doi: 10.1007/s10165-012-0746-2.

PMID:
22975733
13.

Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.

Nakashima Y, Kondo M, Fukuda T, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Maekawa M, Nishizaka H, Nagamine R, Nakashima H, Otsuka T, Shono E, Suematsu E, Shimauchi T, Tsuru T, Wada K, Yoshizawa S, Yoshizawa S, Iwamoto Y.

Mod Rheumatol. 2014 Mar;24(2):258-64. doi: 10.3109/14397595.2013.854069.

PMID:
24593201
14.

Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.

Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N.

Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y.

PMID:
23099471
15.

Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis.

Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, Morales-Torres J, Sanchez-Ortiz A, Sandoval-Castro C, Padilla-Ibarra J, Hernandez-Cuevas C, Ramos-Remus C.

J Rheumatol. 2013 Jul;40(7):1069-73. doi: 10.3899/jrheum.121427.

PMID:
23729804
16.

Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yaguramaki H, Yamanaka H.

J Rheumatol. 2014 Jan;41(1):15-23. doi: 10.3899/jrheum.130466.

17.

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.

Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, Sebba A, Pilson R, Williams S, Van Vollenhoven R.

J Rheumatol. 2013 Jun;40(6):768-80. doi: 10.3899/jrheum.120687.

PMID:
23457383
18.

Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice.

Narváez J, Magallares B, Díaz Torné C, Hernández MV, Reina D, Corominas H, Sanmartí R, LLobet JM, Rodriguez de la Serna A, Nolla JM.

Semin Arthritis Rheum. 2016 Feb;45(4):386-90. doi: 10.1016/j.semarthrit.2015.07.001.

PMID:
26254548
19.

Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.

Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S.

J Rheumatol. 2013 Jul;40(7):1074-81. doi: 10.3899/jrheum.121389.

PMID:
23637318
20.

A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study.

Yabe Y, Kojima T, Kaneko A, Asai N, Kobayakawa T, Ishiguro N.

Mod Rheumatol. 2013 Mar;23(2):245-53. doi: 10.1007/s10165-012-0648-3.

PMID:
22526833
Items per page

Supplemental Content

Support Center